Cargando…
Challenges and management of neurological and psychiatric manifestations in SARS-CoV-2 (COVID-19) patients
COVID-19 is a pandemic caused by human coronavirus (HCoV) SARS-CoV-2, which originated in Wuhan, China, at the end of 2019 and spread globally during 2020. Due to the difficulty of clinical decision-making during this period, our study group reviewed current literature focusing on the neurological a...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7410516/ https://www.ncbi.nlm.nih.gov/pubmed/32767055 http://dx.doi.org/10.1007/s10072-020-04544-w |
_version_ | 1783568254730502144 |
---|---|
author | Orsini, Alessandro Corsi, Martina Santangelo, Andrea Riva, Antonella Peroni, Diego Foiadelli, Thomas Savasta, Salvatore Striano, Pasquale |
author_facet | Orsini, Alessandro Corsi, Martina Santangelo, Andrea Riva, Antonella Peroni, Diego Foiadelli, Thomas Savasta, Salvatore Striano, Pasquale |
author_sort | Orsini, Alessandro |
collection | PubMed |
description | COVID-19 is a pandemic caused by human coronavirus (HCoV) SARS-CoV-2, which originated in Wuhan, China, at the end of 2019 and spread globally during 2020. Due to the difficulty of clinical decision-making during this period, our study group reviewed current literature focusing on the neurological and psychiatric aspects of COVID-19. Despite the knowledge on this newly discovered virus which is constantly evolving, different pieces of evidence reported an association between COVID-19 and neurological symptoms like headache, dizziness, taste and smell disorders and complications involving the nervous system eventually triggered by the pathologic processes elicited by SARS-CoV-2. It seems that younger patients are less prone to develop severe forms of COVID-19. However, neurological signs have been reported in paediatric patients as well, and in some cases, the infection presented neurological sequelae. Furthermore, children with particular neurological diseases or treated with specific drugs (e.g. immune-suppressant therapies) must be carefully monitored during this pandemic. Neurologists should be aware of the main drug–drug interactions and the neurological side effects of COVID-19 treatments. Notably, adverse mental health impact has been reported in patients with SARS-CoV-2, which could be related either to the social strain or to the eventual neurotropic effects of the virus, which in other infections have been proven to promote the onset of psychiatric symptoms. Further, psychiatric population may be more vulnerable to the infection and at higher risk for adverse outcomes. |
format | Online Article Text |
id | pubmed-7410516 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-74105162020-08-07 Challenges and management of neurological and psychiatric manifestations in SARS-CoV-2 (COVID-19) patients Orsini, Alessandro Corsi, Martina Santangelo, Andrea Riva, Antonella Peroni, Diego Foiadelli, Thomas Savasta, Salvatore Striano, Pasquale Neurol Sci Covid-19 COVID-19 is a pandemic caused by human coronavirus (HCoV) SARS-CoV-2, which originated in Wuhan, China, at the end of 2019 and spread globally during 2020. Due to the difficulty of clinical decision-making during this period, our study group reviewed current literature focusing on the neurological and psychiatric aspects of COVID-19. Despite the knowledge on this newly discovered virus which is constantly evolving, different pieces of evidence reported an association between COVID-19 and neurological symptoms like headache, dizziness, taste and smell disorders and complications involving the nervous system eventually triggered by the pathologic processes elicited by SARS-CoV-2. It seems that younger patients are less prone to develop severe forms of COVID-19. However, neurological signs have been reported in paediatric patients as well, and in some cases, the infection presented neurological sequelae. Furthermore, children with particular neurological diseases or treated with specific drugs (e.g. immune-suppressant therapies) must be carefully monitored during this pandemic. Neurologists should be aware of the main drug–drug interactions and the neurological side effects of COVID-19 treatments. Notably, adverse mental health impact has been reported in patients with SARS-CoV-2, which could be related either to the social strain or to the eventual neurotropic effects of the virus, which in other infections have been proven to promote the onset of psychiatric symptoms. Further, psychiatric population may be more vulnerable to the infection and at higher risk for adverse outcomes. Springer International Publishing 2020-08-06 2020 /pmc/articles/PMC7410516/ /pubmed/32767055 http://dx.doi.org/10.1007/s10072-020-04544-w Text en © Fondazione Società Italiana di Neurologia 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Covid-19 Orsini, Alessandro Corsi, Martina Santangelo, Andrea Riva, Antonella Peroni, Diego Foiadelli, Thomas Savasta, Salvatore Striano, Pasquale Challenges and management of neurological and psychiatric manifestations in SARS-CoV-2 (COVID-19) patients |
title | Challenges and management of neurological and psychiatric manifestations in SARS-CoV-2 (COVID-19) patients |
title_full | Challenges and management of neurological and psychiatric manifestations in SARS-CoV-2 (COVID-19) patients |
title_fullStr | Challenges and management of neurological and psychiatric manifestations in SARS-CoV-2 (COVID-19) patients |
title_full_unstemmed | Challenges and management of neurological and psychiatric manifestations in SARS-CoV-2 (COVID-19) patients |
title_short | Challenges and management of neurological and psychiatric manifestations in SARS-CoV-2 (COVID-19) patients |
title_sort | challenges and management of neurological and psychiatric manifestations in sars-cov-2 (covid-19) patients |
topic | Covid-19 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7410516/ https://www.ncbi.nlm.nih.gov/pubmed/32767055 http://dx.doi.org/10.1007/s10072-020-04544-w |
work_keys_str_mv | AT orsinialessandro challengesandmanagementofneurologicalandpsychiatricmanifestationsinsarscov2covid19patients AT corsimartina challengesandmanagementofneurologicalandpsychiatricmanifestationsinsarscov2covid19patients AT santangeloandrea challengesandmanagementofneurologicalandpsychiatricmanifestationsinsarscov2covid19patients AT rivaantonella challengesandmanagementofneurologicalandpsychiatricmanifestationsinsarscov2covid19patients AT peronidiego challengesandmanagementofneurologicalandpsychiatricmanifestationsinsarscov2covid19patients AT foiadellithomas challengesandmanagementofneurologicalandpsychiatricmanifestationsinsarscov2covid19patients AT savastasalvatore challengesandmanagementofneurologicalandpsychiatricmanifestationsinsarscov2covid19patients AT strianopasquale challengesandmanagementofneurologicalandpsychiatricmanifestationsinsarscov2covid19patients |